Modulation of hair growth
Mammalian hair growth may be modulated by applying to the skin a compound that induces or activates the conjugation of an androgen.
Claims
1. A method of inducing or activating uridine diphosphate-glucouronosyltransferase to catalyze conjugation of an androgen involved in hair growth with glucuronic acid or inducing or activating a sulfotransferase to catalyze conjugation of an androgen involved in hair growth with a sulfonate to reduce mammalian androgen-stimulated hair growth, which comprises
- selecting an area of skin from which hair grows in response to androgen-stimulation and from which reduced hair growth is desired; and
- applying to said area of skin a dermatologically acceptable composition comprising an effective amount of a compound that induces or activates said uridine diphosphate-glucouronosyltransferase to catalyze conjugation of said androgen with glucuronic acid or induces or activates said sulfotransferase to catalyze conjugation of said androgen with a sulfonate so that hair growth is reduced from said area of skin.
2. A method of inducing or activating uridine diphosphate-glucouronosyltransferase to catalyze conjugation of an androgen involved in hair growth with glucuronic acid or inducing or activating a sulfotransferase to catalyze conjugation of an androgen involved in hair growth with a sulfonate to increase growth of mammalian hair that does not grow in response to androgen-stimulation, which comprises
- selecting an area of skin from which hair that does not grow in response to androgen-stimulation and from which increased hair growth is desired; and
- applying to said area of skin a dermatologically acceptable composition comprising an effective amount of a compound that induces or activates said uridine diphosphate-glucouronosyltrasferase to catalyze conjugation of said androgen with glucuronic acid or induces or activates said sulfotransferase to catalyze conjugation of said androgen with a sulfonate so that hair growth is increased from said area of skin, wherein said compound is not flavone or a flavone derivative.
3. The method of claim 1 or 2, wherein said compound comprises ethoxyquin.
4. The method of claim 1, or wherein said compound comprises 5,7-dihydroxy-4'-methoxyflavone.
5. The method of claim 1 or 2, wherein said compound comprises butylhydroxyanisole.
6. The method of claim 1 or 2, wherein said compound comprises phenobarbital.
7. The method of claim 1, wherein said compound comprises naringenin.
8. The method of claim 1 or 2, wherein said compound comprises butylhydroxytoluene.
9. The method of claim 1, wherein said compound comprises flavone.
10. The method of claim 1 or 2, wherein said compound comprises tioconazole.
11. The method of claim 1, wherein said compound comprises trans-1,2-bis(2-pyridyl)ethylene.
12. The method of claim 1, wherein said compound comprises 7,4'-isoflavandiol.
13. The method of claim 1, wherein said compound comprises galangin.
14. The method of claim 1, wherein said compound comprises 7-hydroxy-4'-methoxyisoflavone.
15. The method of claim 1, wherein said compound comprises 5,4'-dihydroxy-7-methoxyisoflavone.
16. The method of claim 1, wherein said compound comprises daidzein.
17. The method of claim 1, wherein said compound induces or activates the diphosphate-glucouronosyltransferase to catalyze conjugation of said androgen with glucuronic acid.
18. The method of claim 2, wherein said compound induces or activates the sulfotransferase to catalyze conjugation of said androgen with a sulfonate.
19. The method of claim 1 or 2, wherein said androgen comprises testosterone.
20. The method of claim 1 or 2, wherein the concentration of said compound in said composition is between 0.1% and 30%.
21. The method of claim 1 or 2, wherein the composition provides a reduction in hair growth of at least 15% when tested in the Golden Syrian hamster assay.
22. The method of claim 1 or 2, wherein the composition provides a reduction in hair growth of at least 40% when tested in the Golden Syrian hamster assay.
23. The method of claim 1 or 2, wherein said mammal is a human.
24. The method of claim 1, wherein the area of skin is on the face of the human.
25. The method of claim 24, wherein said human is a woman suffering from hirsutism.
26. The method of claim 2, wherein the area of skin is on the scalp of a human.
27. A method of conjugating an androgen that stimulates androgen-stimulated hair growth to produce a conjugate of said androgen that is more readily eliminated from the body than said androgen to reduce mammalian androgen-stimulated hair growth, which comprises
- selecting an area of skin from which hair grows in response to androgen-stimulation and from which reduced hair growth is desired; and
- applying to said area of skin a dermatoligically acceptable composition comprising an effective amount of a compound that induces or activates the conjugation of said androgen to produce said conjugate so that hair growth is reduced from said area of skin.
28. The method of claim 27, wherein the area of skin is on the face of a human.
29. A method of conjugating an androgen that retards growth of hair that does not grow in response to androgen-stimulation to increase growth of mammalian hair that does not grow in response to androgen-stimulation, which comprises
- selecting an area of skin from which hair does not grow in response to androgen-stimulation and from which increased hair growth is desired; and
- applying to said area of skin a dermatologically acceptable composition comprising an effective amount of a compound that induces or activates the conjugation of said androgen to produce said conjugate so that hair growth is increased from said area of skin, wherein said compound is not flavone or a flavone derivative.
30. The method of claim 29, wherein the area of skin includes the scalp of a human.
31. The method of claim 27 or 29, wherein the compound is an inducer or activator of an androgen conjugation enzyme.
32. The method of claim 31, wherein the androgen comprises a testosterone.
33. The method of claim 31, wherein the androgen comprises dihydrotestosterone.
34. The method of claim 31, wherein the androgen comprises an androgen selected from the group consisting of androstenedione, androstenediols, and dehydroepiandrosterone.
35. A method of inducing or activating conversion of testosterone to a less active metabolite to reduce mammalian androgen-stimulated hair growth, which comprises
- selecting an area of skin from which hair grows in response to androgen-stimulation and from which reduced hair growth is desired; and
- applying to said area of skin a dermatologically acceptable composition comprising an effective amount of a compound that induces or activates the conversion of testosterone to said less active metabolite so that the hair growth is reduced form the area of skin.
36. The method of claim 35, wherein the area of skin is on the face of a human.
37. The method of claim 35, wherein the less active metabolite comprises a compound that is more water soluble than testosterone.
38. A method of inducing or activating conversion of testosterone to a less active metabolite to increase hair growth form the scalp of a human, which comprises
- selecting an area of the scalp of a human and from which increase hair growth is desired; and
- applying to the area of the scalp a dermatologically acceptable composition comprising an effective amount a compound that induces or activates the conversion of testosterone to said less active metabolite so that hair growth increases from the area of the scalp, wherein said compound is not flavone or a flavone derivative.
39. The method of claim 38, wherein the less active metabolite comprises a compound that is more water soluble than testosterone.
3426137 | February 1969 | Philpitt et al. |
4039669 | August 2, 1977 | Beylar et al. |
4139638 | February 13, 1979 | Neri et al. |
4161540 | July 17, 1979 | Neri et al. |
4191775 | March 4, 1980 | Glen |
4269831 | May 26, 1981 | Ferrari et al. |
4370315 | January 25, 1983 | Greff et al. |
4439432 | March 27, 1984 | Peat |
4508714 | April 2, 1985 | Cecic et al. |
4517175 | May 14, 1985 | Iwabuchi et al. |
4720489 | January 19, 1988 | Shander |
4885289 | December 5, 1989 | Breuer et al. |
4935231 | June 19, 1990 | Pigiet |
5095007 | March 10, 1992 | Ahluwalia |
5096911 | March 17, 1992 | Ahluwalia et al. |
5132293 | July 21, 1992 | Shander et al. |
5143925 | September 1, 1992 | Shander et al. |
5189212 | February 23, 1993 | Ruenitz |
5271942 | December 21, 1993 | Haverhagen |
5300284 | April 5, 1994 | Wiechers et al. |
5364885 | November 15, 1994 | Ahluwalia et al. |
5411991 | May 2, 1995 | Shander et al. |
5455234 | October 3, 1995 | Ahluwalia et al. |
5474763 | December 12, 1995 | Shander et al. |
5554608 | September 10, 1996 | Ahluwalia et al. |
5648394 | July 15, 1997 | Boxall et al. |
0 413 528 A1 | February 1991 | EPX |
0 532 219 A2 | March 1993 | EPX |
1 458 349 | December 1976 | GBX |
WO 96/10387 | April 1996 | WOX |
- Pegg et al., "Fundam. Appl. Toxicol.", vol. 32(1):45-32, (1996) (Abstract only). Andrew G. Messenger, "The Control of Hair Growth: An Overview", The Society for Investigative Dermatology, Inc., 1993. Green et al., "Cloning and Expression of a Rat Liver Phenobarbital-Inducible UDP-Glucuronosyltransferase (2B12) with Specificity for Monoterpenoid Alcohols", Arch. of Biochem. & Biophysics, vol. 322, Oct. 1, 1995. Wong et al., "Differential Induction of UDP-Glucuronosyltransferase Activity and Gene Expression in Rat Liver", Pharmaceutical Research, vol. 12, No. 7, 1995. Sun et al., "Flavonoids increased the activity of Testosterone Glucuronosyltransferase (GT) in prostate cancer cells", Proceedings of the American Association for Cancer Research, vol. 36, Mar. 1995 (Abstract). Kashfi et al., "Regulation of Uridine Diphosphate Glucuronosyltransferase Expression by Phenolic Antioxidants", Cancer Research, 54, pp. 5856-5859, Nov. 15, 1994. Pritchard et al., "A Recombinant Phenobarbital-Inducible Rat Liver UDP-Glucoronsyltransferase (UDP-Glucuro-nosyltransferase 2B1) Stably Expressed in V79 Cells Catalyzes . . . " Molecular Pharmacology, 45:42-50, 1993. Chen et al., "Characterization of a Cloned Human Dihydrotestosterone/Androstanediol UDP-Glucuronosyltrans-ferase and Its Comparison to Other Steroid Isoforms", Biochemistry, vol. 32, No. 40, 10648-57, 1993. Michael R. Franklin, "Drug Metabolizing Enzyme Induction by Simple Diaryl Pydridines; 2-Substituted Isomers Selectively Increase Only Conjugation Enzyme Activities . . . ", Toxicology and Applied Pharmacology, 111, 1991. J. Baron, "In situ sites for xenobiotic activation and detoxication: Implications for the differential susceptibility of cells to the toxic . . . ", Progress in Histo-and Cytochemistry, vol. 23, 1991. Tephyl et al., "UDP-glucuronosyltransferases: a family of detoxifying enzymes", TIPS Reviews, Jul. 1990. Ritter et al., "Induction of Hepatic Oxidative and Conjugative Drug Metabolism in the Hamster by N-Substituted Imidazoles", Toxicology Letters, 36, pp. 51-59, 1987. Schweikert et al., Regulation of Human Hair Growth by Steroid Hormones, JCE&M, vol. 38, No. 5, 1974. Adachi et al., "Human Hair Follicles: Metabolism and Control Mechanisms", Journal of the Society of Cosmetic Chemists, 21, 901-924, Dec. 9, 1970. Marty E. Sawaya, "Steroid Chemistry and Hormone Controls during the Hair Follicle Cycle", Annals New York Academy of Sciences, pp. 376-384 (Undated). CA 123:4198, Kudlacek et, 1995. CA 125:293042, Ahlowaha et al, 1996.
Type: Grant
Filed: Jan 20, 1998
Date of Patent: Sep 28, 1999
Inventors: Peter Styczynski (Mt. Airy, MD), Gurpreet S. Ahluwalia (Gaithersburg, MD)
Primary Examiner: Rebecca Cook
Law Firm: Fish & Richardson P.C.
Application Number: 9/9,213
International Classification: A61K 3147;